Keymed Biosciences Gains NMPA Approval for Phase I/II Study of CM518D1
China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received approval from the National...
Keymed Biosciences
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-1819 in Allergic Rhinitis Study
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval...
NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter
NewCo is a new transaction model developed by Chinese innovative drug companies in response to...
Keymed Biosciences’ Kangyueda Gains NMPA Approval for Seasonal Allergic Rhinitis
China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received another indication approval from...
Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium
China-based Keymed Biosciences Inc. (HKG: 2162) and InnoCare Pharma (HKG: 9969, SHA: 688428) have jointly...
Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development
China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm...
Keymed Biosciences’ Kangyueda Approved for CRSwNP Treatment in China
China-based Keymed Biosciences Inc., (HKG: 2162) has announced that it has received another indication approval...
Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting
China-based Keymed Biosciences Inc., (HKG: 2162) has announced the presentation of the latest data from...
Jiangsu Hengrui Medicine’s SHR-1819 Receives NMPA Approval for Atopic Dermatitis Clinical Trial
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
Keymed Biosciences Enters Global Licensing Agreement with Platina Medicines for CM336
Keymed Biosciences Inc., a China-based biopharmaceutical company (HKG: 2162), has announced a significant licensing agreement...
Keymed Biosciences’ Stapokibart Receives First Prescription in China for IL-4Rα Targeting Therapy
China-based biotech company Keymed Biosciences Inc. (HKG: 2162) has reached a significant milestone with its...
Keymed Biosciences’ IL-4Rα mAb Stapokibart Receives NMPA Approval for Atopic Dermatitis Treatment
Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has announced that the...
Keymed Biosciences Strikes Licensing Deal with Belenos Biosciences for Global BsAb Rights
Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has entered into a...
Keymed Biosciences’ CM313 Shows Promise in Treating Immune Thrombocytopenia, NEJM Study Says
Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has published results from...
Keymed Biosciences’ Stapokibart Earns Priority Review for Chronic Sinusitis Treatment in China
Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced that its...
China’s CDE Gives Tacit Approval to Keymed Biosciences’ Alzheimer’s Drug CM383 for Clinical Trials
The Center for Drug Evaluation (CDE) has indicated on its website that China-based Keymed Biosciences...
Keymed Biosciences’ IL-4Rα Monoclonal Antibody for Allergic Rhinitis Accepted by China NMPA
China-based biopharmaceutical company Keymed Biosciences Inc. (HKG: 2162) has announced that the National Medical Products...
Keymed Biosciences’ Stapokibart Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Study
China-based biopharmaceutical company Keymed Biosciences Inc. (HKG: 2162) has announced that its IL-4Rα monoclonal antibody...
Keymed Biosciences Achieves First Dosing in Global Phase III Trial for Claudin 18.2 Targeting ADC
Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced the completion...
Keymed Biosciences’ Stapokibart Filing Accepted for Priority Review in China for Atopic Dermatitis
Keymed Biosciences Inc. (HKG: 2162) has announced that its market filing for stapokibart (CM310), a...